These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12839702)

  • 1. Why do we need to eradicate pathogens in respiratory tract infections?
    Garau J
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S5-12. PubMed ID: 12839702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections.
    Klugman KP
    Eur Respir J Suppl; 2002 Jul; 36():3s-8s. PubMed ID: 12168746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications for antimicrobial prescribing of strategies based on bacterial eradication.
    Klugman KP
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S27-31. PubMed ID: 12839705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg?
    Garau J
    Respir Med; 2001 Jun; 95 Suppl A():S5-11; discussion S26-7. PubMed ID: 11419672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptococcus pneumoniae: epidemiology and patterns of resistance.
    Jacobs MR
    Am J Med; 2004 Aug; 117 Suppl 3A():3S-15S. PubMed ID: 15360092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
    Sakata H
    Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154
    [No Abstract]   [Full Text] [Related]  

  • 16. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.
    Dagan R
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S21-6. PubMed ID: 12839704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacterial resistance and pharmacodynamics as the basis for prescribing antibiotics in respiratory infections].
    Aguado-García JM; Martín-Herrero JE; Lumbreras-Bermejo C
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):230-7. PubMed ID: 15056440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide resistance: an increasing concern for treatment failure in children.
    Jacobs MR; Johnson CE
    Pediatr Infect Dis J; 2003 Aug; 22(8 Suppl):S131-8. PubMed ID: 14566999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.